Metotrexato Teva

Methotrexate, the active ingredient in Metotrexato Teva, is a antimetabolite (folate antagonist) presented as a generic formulation for epidural, intrabursal and intracoronary use. It is employed as a disease‑modifying antirheumatic drug and anticancer agent in adult and pediatric patients.

GNH USA supplies Metotrexato Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Methotrexate acts on rapidly dividing cells and immune pathways, providing therapeutic benefit across several disease families. - Rheumatoid arthritis: reduces disease activity, joint inflammation and structural damage. - Psoriasis: improves skin lesions and decreases severity scores. - Acute lymphoblastic leukemia: induces remission by inhibiting malignant cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumor control as part of combination regimens. - Ectopic pregnancy: terminates trophoblastic tissue when surgical options are not chosen.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset often occurring after dosing. - Fatigue: persistent tiredness not explained by disease activity. - Oral mucositis: painful sores or ulceration of the mouth lining. - Cytopenias: mild reductions in white blood cells, neutrophils or platelets. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Severe hepatic toxicity: potential for fibrosis or cirrhosis with prolonged use. - Pulmonary fibrosis: interstitial lung disease presenting with cough and dyspnea. - Life‑threatening infection: due to profound bone‑marrow suppression. - Renal failure: acute kidney injury from precipitation of drug crystals. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Methotrexate requires careful monitoring and specific safety measures. - Baseline assessment: obtain complete blood count, liver and renal function tests before initiating therapy. - Regular monitoring: repeat hematology and biochemistry at intervals recommended by the prescriber. - Pregnancy avoidance: contraindicated in pregnancy (Category X); effective contraception must be used. - Breastfeeding restriction: drug is excreted in milk; breastfeeding is not advised. - Drug interactions: review concomitant medications for agents that may increase toxicity. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Methotrexate can interact with several medicines, altering its safety profile.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate plasma levels and toxicity. - Penicillins and other β‑lactam antibiotics: may reduce renal clearance, raising exposure. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine or other immunosuppressants: additive bone‑marrow suppression. - Proton‑pump inhibitors: may modestly increase methotrexate concentrations.